The message to Medtronic’s (NYSE:MDT) spine business from chairman and CEO Omar Ishrak was clear today: Shape up or ship out.
During a conference call with analysts to discuss the med-tech titan’s fiscal 3rd-quarter results, Ishrak said he was “not happy” that the division posted a 9% revenue decline and warned that the spine unit must raise its game or face the consequences.
A stealthy Minnesota medical device company is moving ahead with plans to develop a minimally invasive approach to bariatric surgery and better solve the problem of Type II diabetes.
MetaModix is one-third of the way through a $1.9 million angel round, according to a federal regulatory filing and company executives. It is using the money to develop its product and perform some preclinical testing. MetaModix hopes to be in European clinical trials by early next year, said Kedar Belhe, the company’s chief executive officer.
MassDevice Network
@MassDevice
LinkedIn
YouTube